The great bet of pharmaceutical innovation

Thanks to the huge expenditures in Research and Development in the pharmaceutical field in recent decades, medicine has been able to count on continuous innovations that have allowed a continuous improvement in the possibilities of treating human beings.

As with the discoveries of recent decades, today and in the next 10 years we are and will be in a phase of launching new molecules that will have a major impact on the lives of each of us. As happened for Hepatitis C, in the near future we will have very effective but at the same time expensive drugs at hand: today's challenge is to leave no one behind, despite the presence of an increasingly elderly and polymorbid population, and therefore to an increasingly broader demand for care.

The ethical problem of access is the real, great challenge for the institutions in the near future. In healthcare, in parallel with new discoveries and significant improvements in the possibilities of treatment, there is always a greater financial requirement to guarantee access. In an economic-financial framework such as the current one, guaranteeing access for all to new therapies is a difficult task.

Studio I-Com – 30-09-2015

Year: 2015
No. of pages: 88
Authors: Cinzia ARU, Maria Rosaria DELLA PORTA, Davide INTEGLIA, Eleonora MAZZONI

I-Com study
Index

________________________________________________________

THE-Com, Institute for Competitiveness, he organized last September 30th The conference public “THE BIG BET OF PHARMACEUTICAL INNOVATION. New therapies, access and economic and industrial sustainability”. The event took place at Rome give her 9.00 at 2.00 pm at the Coffee House Of Colonna Palace, in Piazza dei Santi Apostoli, 67.

The conference compared the main stakeholders of the healthcare and industrial systems on the scenarios linked to the arrival of innovative therapies, unprecedented in recent decades, and on the possible responses of the competent institutions to ensure, on the one hand, the greatest possible benefits for patients and on the other, the economic sustainability of the NHS. This without neglecting the industrial profiles, linked to the possibility for Italy to host the production and research relating to the new molecules being marketed. At the event, one was presented study which intends to analyze and deepen the main issues addressed in the debate.

In the final plenary, the topics discussed and the main outputs of each I-Group were presented, divided as follows:

I-Group 1 – The great bet of access to innovative treatments
I-Group 2 – The great challenge of economic and industrial sustainability

Plan
I-Com presentation
I-Com study
Press release
Message from the Minister of Health Beatrice Lorenzin